Adherium Receives U.S. FDA Clearance For GSK PMDI Inhaler Users To Remotely Monitor Physiological Parameters - Kalkine Media

Follow us on Google News:
 Adherium Receives U.S. FDA Clearance For GSK PMDI Inhaler Users To Remotely Monitor Physiological Parameters
Image source: ©2022 Kalkine Media®

Nov 28 (Reuters) - Adherium Ltd:


* RECEIVED U.S. FDA CLEARANCE FOR GSK PMDI INHALER USERS TO REMOTELY MONITOR PHYSIOLOGICAL PARAMETERS Source text for Eikon: Further company coverage: (Reporting by Poonam Behura)

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.